EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia

Lynette Chee iD, Nora Lee, Andrew Grigg iD, Melissa Chen, Anthony Schwarer, Jeff Szer iD, Sumita Ratnasingam, Sonia Raj, Pohan Lukito, David Yeung, Timothy Hughes, Naranie Shanmuganathan

Internal Medicine Journal · 2024

DOI: 10.1111/imj.16446 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal Medicine Journal, 2024. Verfasst von Lynette Chee und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Haematology, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Protein Kinase Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Asciminib is a novel allosteric STAMP (specifically targets the ABL myristoyl pocket) inhibitor of the BCR::ABL1 oncogene. Real‐world clinical outcomes of patients with tyrosine kinase inhibitor (TKI)‐resistant/intolerant chronic myeloid leukaemia (CML) in Australia on the Managed Access Programme for asciminib showed higher molecular responses for those with intolerance versus resistance ± intolerance to their last TKI. There remains a clinical need to improve outcomes in patients with CML who have resistance to multiple TKIs, especially in the ponatinib‐pretreated cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsHumansAustraliaMaleMiddle AgedFemaleTreatment OutcomeAgedAdultDrug Resistance, NeoplasmFusion Proteins, bcr-ablAntineoplastic AgentsPyridazinesAged, 80 and overNiacinamidePyrazoles

Stichwörter der Autor:innen

asciminibchronic myeloid leukaemiatyrosine kinase inhibitor

Substanzen

asciminibProtein Kinase InhibitorsFusion Proteins, bcr-ablAntineoplastic AgentsPyridazinesNiacinamidePyrazoles

Autor:innen und Institutionen

  • Department of Clinical Haematology, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.
  • Bendigo Cancer Centre, Bendigo Hospital, Bendigo, Victoria, Australia.
  • Department of Clinical Haematology, Austin Health, Melbourne, Victoria, Australia.
  • Monash Haematology, Monash Health, Melbourne, Victoria, Australia.
  • Department of Haematology, Box Hill Hospital, Melbourne, Victoria, Australia.

ORCID-Profile: Lynette Chee, Andrew Grigg, Jeff Szer

Zitieren

APA

Chee, L., Lee, N., Grigg, A., Chen, M., Schwarer, A., Szer, J., Ratnasingam, S., Raj, S., Lukito, P., Yeung, D., Hughes, T., & Shanmuganathan, N. (2024). Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia. Internal Medicine Journal. https://doi.org/10.1111/imj.16446

Vancouver

Chee L, Lee N, Grigg A, Chen M, Schwarer A, Szer J, et al. Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia. Internal Medicine Journal. 2024. doi:10.1111/imj.16446

BibTeX
@article{Chee2024,
  author = {Chee, Lynette and Lee, Nora and Grigg, Andrew and Chen, Melissa and Schwarer, Anthony and Szer, Jeff and Ratnasingam, Sumita and Raj, Sonia and Lukito, Pohan and Yeung, David and Hughes, Timothy and Shanmuganathan, Naranie},
  title = {Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia},
  journal = {Internal Medicine Journal},
  year = {2024},
  doi = {10.1111/imj.16446}
}
Kostenlos starten →